Compare Abeona Therapeutics Inc (ABEO) vs Google Inc (GOOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Google Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Google Inc trades at $358 (market cap $4.46T). The key difference: Google Inc is far larger — about 11946.9× Abeona Therapeutics Inc's market cap, and Google Inc pays a 0.24% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | GOOG | |
|---|---|---|
Market Cap | $373.32M | $4.46T |
Sector | Health | Technology |
52-Week High | $7.23 | $399.06 |
52-Week Low | $4.17 | $175.16 |
Enterprise Value | $228.22M | $4.42T |
Volume | — | 1,511,127 |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
GOOG trades at $363.62, up 2.09% today, reflecting strong momentum after consecutive earnings beats. The stock shows a bullish technical trend with support at $358 and resistance at $369. Revenue grew to $402.84B in 2025, with net income reaching $132.17B, driven by robust profitability margins. Recent news highlights Google's AI advancements and a dividend payment, reinforcing investor confidence.
Outlook remains positive with a consensus price target of $457.50, indicating 26% upside. Risks include competitive pressures in AI and regulatory scrutiny. Analyst sentiment is overwhelmingly bullish (86.84% buy ratings), supported by strong cash flow growth and strategic investments in fusion technology and AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
